



CLASSIC MOTOR WORKING GROUP of the PARKINSON STUDY GROUP

Introduction

The PSG has a well-developed research infrastructure and wide interdisciplinary membership across many institutions with diverse geographic locations and scientific strengths. Thus, the PSG, using the facilitation by the Classic Motor Working Group (CMWG), is uniquely poised to advance clinical research on recognition, assessment, and treatment of classic motor manifestations of PD.

Goals of CMWG

To increase awareness and understanding of classic motor aspects of PD within PSG, among clinicians, researchers, and funding agencies,

To provide a forum for the generation, development, execution, and dissemination of interdisciplinary clinical research studies that lead to improved understanding and treatments of the classic motor aspects of PD, including single and multi-site trials and other clinical protocols, retrospective studies on existing databases (“data mining projects”), and review and position papers,

To foster the development of new investigators across multiple disciplines with greater expertise in the classic motor aspects of PD and the related research,

To counsel appropriate PSG bodies (e.g., Executive Committee, Scientific Review Committee, Mentoring Committee, steering committees of clinical trials) and collaborate with other working groups of PSG on clinical studies that lead to more effective treatments of classic motor aspects of PD.

Potential Scope of WG Activity on Classic Motor Aspects of PD

Project classification:

1. Interventional Trials:
 - a. Pharmaceutical
 - b. Non-pharmaceutical
2. Non-interventional Studies
 - a. Retrospective
 - i. Secondary analysis of PSG databases (“data mining”)
 - ii. Analysis of external databases
 - b. Prospective (descriptive or experimental)
 - i. Epidemiology
 - ii. Clinical features (course, features, associated factors)
 - iii. Genetics
 - iv. Imaging
 - v. Pathology
 - vi. Other
 - vii. Combined approach
 - c. Clinical practice parameters
 - i. Review/consensus panels for evaluation/development of assessment tools
 - ii. Review/consensus panels for treatment strategies

Tony Lang, MD
Chair

Tanya Simuni, MD
Co-Chair

Alberto Espay, MD, MSC
Co-Chair

September 2011